Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Anesthesia Drugs May Relieve Depression in Some

By HospiMedica International staff writers
Posted on 05 Apr 2010
A pilot study has found that repeated low doses of the anesthesia drug ketamine produced almost immediate relief from depression in patients with treatment-resistant depression (TRD) who did not respond to any other type of depression therapy.

Researchers at Mount Sinai School of Medicine (New York, NY, USA) and the University of Groningen (The Netherlands) studied the effects of repeated doses of ketamine in 10 medication-free symptomatic patients with TRD, who had previously shown a meaningful antidepressant response to a single dose of the drug. More...
The study protocol involved six intra-venous (IV) infusions of ketamine over 12 days; on day 1, the patients received a 40-min infusion of ketamine (0.5 mg/kg), in an inpatient setting with continuous vital-sign monitoring. Psychotomimetic and adverse events were recorded repeatedly, with the primary efficacy measure being change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) score. If the patients showed a 50% or higher reduction in MADRS scores on day 2, they received five additional infusions on an outpatient basis (days 3, 5, 8, 10, and 12). Follow-up visits were conducted twice weekly for four weeks, or until relapse.

The results showed that the response criterion was met by nine patients after the first infusion, and again after the sixth infusion, with the mean reduction in MADRS scores after the sixth infusion being 85%. Postketamine, eight of nine patients relapsed, on average, 19 days after the last infusion, with one patient remaining antidepressant-free with minimal depressive symptoms for over 3 months. The ketamine elicited minimal positive psychotic symptoms, with three patients experiencing significant but transient dissociative symptoms. The side effects during and after each ketamine infusion were generally mild. The study was published in the January 15, 2010, issue of Biological Psychiatry.

"These pilot findings suggest feasibility of repeated-dose intravenous ketamine for the acute treatment of treatment-resistant depression,” concluded lead author Marije aan het Rota, Ph.D., of the University of Groningen, and colleagues.

Ketamine is classified as an N-methyl d-aspartate (NMDA) receptor antagonist. At anesthetic level doses, ketamine has also been found to bind to opioid μ receptors and σ receptors. Like other drugs of this class, such phencyclidine (PCP, or "angel dust”), it induces a state referred to as "dissociative anesthesia,” often used as a recreational drug. Ketamine has a wide range of effects in humans, including analgesia, anesthesia, elevated blood pressure, and bronchodilation. Ketamine is primarily used for the induction and maintenance of general anesthesia, usually in combination with some sedative drug, and is a popular anesthetic in veterinary medicine.


Related Links:
Mount Sinai School of Medicine
University of Groningen


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Medical-Grade Display
HL2316SHTB
New
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.